Overexpression of SLC38A1 is associated with poorer prognosis in Chinese patients with gastric cancer by Jing Xie et al.
Xie et al. BMC Gastroenterology 2014, 14:70
http://www.biomedcentral.com/1471-230X/14/70RESEARCH ARTICLE Open AccessOverexpression of SLC38A1 is associated with
poorer prognosis in Chinese patients with gastric
cancer
Jing Xie1*†, Ping Li2†, Hui-feng Gao1, Jian-xin Qian3, Ling-Yan Yuan3 and Jie-jun Wang3*Abstract
Background: Current literature has demonstrated that host glutamine depletion facilitates tumorigenesis. Likewise,
the glutamine transporter SLC38A1 is putatively associated with malignant transformation and tumor progression.
Taken together, this forms the premise for undertaking the current study. The twofold aim of this study was to
provide insight into whether or not a variance in the expression of SLC38A1 exists between human gastric cancer
and healthy human tissues, and to determine how silencing the SLC38A1 gene could affect the proliferation,
viability, migration, and invasion of gastric cancer cells.
Methods: Immunohistochemical staining was used to analyze the expression of SLC38A1 in gastric cancer tissues
and adjacent healthy mucosa in 896 patients with pathologically confirmed gastric cancer who had underwent R0
resection. SH-10-TC cells (a gastric cancer cell line) were used to examine whether silencing SLC38A1 with siRNA
could affect cell viability, migration and invasion.
Results: The SLC38A1 protein was very low or undetectable in healthy gastric mucosa. In contrast, strong staining
of SLC38A1 protein was found in the cytoplasm in 495 out of the 896 gastric cancer samples. More pronounced
SLC38A1 expression in gastric cancer tissues was significantly associated with age, differentiation status, lymph
node metastasis, TNM stage and PCNA (proliferating cell nuclear antigen) expression. Upon univariate survival
analysis, SLC38A1 expression was correlated with poor survival. Multivariate survival analysis revealed that SLC38A1
was an independent prognostic factor.
Conclusion: SLC38A1 is overexpressed in gastric cancer, which suggests that it is contributory to tumor
progression. These results encourage the exploration of SLC38A1 as a target for intervention in gastric cancer.
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Amino acid transporters are essential for a variety of
physiological cellular processes, including uptake of nutri-
ents, energy and chemical metabolism, as well as malignant
transformation [1]. Amino acid transporters include system
A (ATA1/SNAT1/SLC38A1, ATA2/SNAT2/SLC38A2 and
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various amino acid transporters, system L-type amino
acid transporter-1 (LAT-1) is up-regulated in a wide
variety of human cancers, including esophageal adeno-
carcinoma [2], oral squamous cell carcinoma [3], colo-
rectal adenocarcinoma [4], and liver cancer [5]. System
A amino acid transporter is also overexpressed in hu-
man cancers [5-8]. System A is a Na+-dependent active
transport system, known to mediate the uptake of amino
acids with small side chains (e.g., alanine, serine, proline
and glutamine) [1]. Its activity is highly influenced by pH,
cell volume, and a variety of hormones, such as insulin,
glucagon, and insulin-like growth factor-I [1].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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distinct types, known as amino acid transporters SLC38A1,
SLC38A2 and SLC38A4 [9]. These transporters belong to
the solute-linked carrier family SLC38, and are differen-
tially expressed among different organs/tissues. SLC38A1
is expressed primarily in the brain and placenta, as op-
posed to the lungs, liver, spleen and kidneys [10]. SLC38A2
is, on the other hand, ubiquitously expressed in mamma-
lian tissues [9], while SLC38A4 is primarily expressed in
the liver [11]. System A transporters are up-regulated in a
range of human cancers, including breast cancer and hepa-
tocellular cancer [6,7].
Our previous studies, using gene chip analysis, sug-
gested elevated SLC38A1 mRNA expression in gastric
cancer (unpublished data). In the current study, we com-
pared the expression of SLC38A1 in gastric carcinoma
in contrast with healthy adjacent gastric mucosa at the
protein level. Potential correlation of SLC38A1 with the
prognosis was examined using a multivariate analysis,
and the biological role of SLC38A1 in proliferation and




This study included 896 patients (median age: 61.4 years;
634 men, 262 women) with histologically confirmed gas-
tric cancer who underwent D2/D3 curative resection at
either Changhai or Changzheng Hospital in Shanghai,
during a period from 2001 to 2005. Subjects who
received neo-adjuvant therapy prior to the surgery were
not included. Subjects with stage III disease also received
a 5-fluorouracil-based chemotherapeutic regimen for 4–
6 cycles. Patients presenting with neuroendocrine tumors,
lymphoma or sarcoma were not included. Adjacent mu-
cosa that was free from cancer cells was used as a healthy
control.
The follow-up was conducted via phone conversation
and mail in March 2010. Information with regards to
survival/death was obtained in 673 cases (median sur-
vival: 59.08 months).
Demographic information and the construction of
TMA blocks were described previously [12-15]. All tis-
sue specimens were obtained with informed consent,
and the use of the human specimens was approved by
Institutional Review Board at Changhai and Changzheng
Hospitals.
Immunohistochemistry (IHC)
Immunohistochemical staining was carried out on 4-μm
paraffin sections after heat-mediated antigen retrieval.
Samples were incubated with a human-anti-rabbit poly-
clonal antibody to SLC38A1 (dilution 1:200; Abcam,
Cambridge, U K) overnight at 4°C. Goat anti-rabbitantibody (dilution 1:4000; Invitrogen, Carlsbad, CA, USA)
was used as a secondary antibody. An immunoglobulin-
negative control was used to rule out non-specific binding.
As for the positive control, we referred to other studies in
liver cells by Nobuo Kondoh [6] and in hilar cholangio-
carcinoma by Yu WL [16], which indicated the SLC38A1
protein was stained brown and diffused in the cytoplasm.
Slides were counterstained with hematoxylin.
Data (staining in cytoplasma) were acquired independ-
ently by two investigators (Guan Zhen Yu and Ying Chen)
blinded to sample nature using an Olympus CX31 micro-
scope (Olympus, Center Valley, PA, USA), and analyzed
using a semi-quantitative scoring system. Staining was
graded on a scale of 0–2 (0 = negative staining [no cyto-
plasmic staining of any tumor cells], 1 = moderate ex-
pression [cytoplasmic staining of <25% of tumor cells],
and 2 = high expression [cytoplasmic staining of ≥25%
of tumor cells]) as described previously [14,17].
Cell culture and siRNA transfection
SH-10-TC cells were obtained from Shanghai Institute
for Biological Sciences, Chinese Academy of Sciences
(CAS), and grown in RPMI-1640 medium containing
10% FBS. Cells were maintained at 37°C in a humidified
atmosphere containing 5% CO2. The experiments were
carried out in the exponential phase of growth.
Four pairs of anti-SLC38A1 siRNAs and randomized
cocktails of dsRNA as a control were synthesized by
GenePharma (Shanghai, China). The siRNA transfection
was carried out using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA).
Western blot analysis
Cell lysate containing 100 μg protein was resolved on
SDS-PAGE, transferred onto PVDF membrane and incu-
bated with an anti-SLC38A1 antibody (dilution, 1:500;
Invitrogen, Carlsbad, CA, USA). Protein bands were eval-
uated using an Odyssey infrared fluorescent scanning sys-
tem (LI-COR Biosciences, Lincoln, NE, USA) and Scion
Image software (NIH, USA). GAPDH was used as an
internal control.
Cell viability
SH-10-TC cells were seeded in 96-well plates at the day
before transfection. Cells were counted at 48 h, 72 h and
96 h after transfection using a microtiter-plate colorimet-
ric WST assay (Cell counting kit-8; Dojindo Laboratories,
Kumamoto, Japan) at 450 nm. Experiments were con-
ducted in triplicate.
Transwell migration and invasion assay
Assays were performed using a modified Boyden chamber
(Corning Costar, Rochester, NY, USA) containing a gelatin-
coated polycarbonate membrane filter (8-μm pore size).
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Matrigel (0.3 mg/ml; BD Biosciences, Bedford, MA, USA).
Transfected cells were harvested with a cell dissociation so-
lution (Invitrogen, Carlsbad, CA, USA) and suspended in
medium with 1% bovine serum albumin.
Cells (1 × 104) were added to the upper compartment
and allowed to migrate for 6 h at 37°C. After 6 h, cells
on the upper side of the membrane were removed with
a cotton swab. Cells on the bottom surface of the mem-
brane were fixed in 3.7% paraformaldehyde, stained with
hematoxylin for quantification. Data were expressed as
the average number of cells per insert.Statistical analysis
The relationship between SLC38A1 expression and clini-
copathologic parameters was analyzed using the chi-
square test. Survival was analyzed using the Kaplan-Meier
method and the log-rank test. The prognostic value of
clinicopathologic parameters was examined using a
Cox proportional hazards regression model for multi-
variate analysis. All tests were two-sided. P < 0.05 was
considered statistically significant. All statistical ana-
lyses were performed using the SPSS statistical software
program for Microsoft Windows (SPSS Inc., Chicago,
IL, USA).Figure 1 Human gastric cancers and healthy mucosa specimens in tis
Representative healthy gastric tissue without SLC38A1 cytoplasmic express
cancer tissues with positive SLC38A1 expression which was cytoplasm stainResults
SLC38A1 protein in gastric cancer
The expression of SLC38A1 protein in the healthy gastric
mucosa was very low or undetectable (Figure 1A). Strong
staining of SLC38A1 protein in the cytoplasm was found
in 495 out of the 896 cancer samples in both the well dif-
ferentiated (Figure 1B), and poorly differentiated cancer
cells (Figure 1C). In the cytoplasm, the SLC38A1 protein
was stained brown and diffused.SLC38A1 expression and clinicopathologic factors
SLC38A1 overexpression was closely associated with
old age (>60 yrs), differentiation status (high/moderate),
regional lymph node metastasis, TNM stage (III), and
positive PCNA expression (Table 1), but not with gen-
der, tumor size, tumor location, operation manner, lym-
phovascular invasion, depth of tumor invasion, and p53
expression.Prognostic factors of overall survival
SLC38A1 expression in cancer tissue was associated with
poorer prognosis. The median survival was 46.69 months
in patients with SLC38A1-positive cancers, and 69.7 months
in subjects with SLC38A1-negative cancers (P = 0.002;
Figure 2). Upon a multivariate analysis, independentsue microarray were stained with an anti-SLC38A1. (A)
ion, (B) Well-differentiated and (C) Morderately-differentiated gastric
ed brown and diffuse. Magnification × 200.
Table 1 Association between SLC38A1 expression and
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Subtotal gastrectomy 400 217
Total gastrectomy 496 278
Size (Diameter) 0.321
≤ 6 cm 706 384




Gastric wall invasion 0.151
T1/T2 308 160
T3/T4 588 335
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expression, differentiation status, lymphovascular invasion,
PCNA expression, size and TNM stage (Table 2).RNAi experiments
Specific knockdown of endogenous SLC38A1 protein
was confirmed by all four siRNAs with Western blot
(Figure 3A). siRNA #2 (si-SLC38A1) reduced the en-
dogenous SLC38A1 transcript by >70%, and was selected
for subsequent experiments.
Compared to parental cells and si-Ctl, si-SLC38A1 de-
creased the proliferation (Figure 3B), as well as the mi-
gration of SH-10-TC cells (Figure 3C), but did not affect
cell passage through Matrigel.Discussion
Consistent with the physiological and pathological roles
of glutamate in cancer development, we found marked
differences in the expression of SLC38A1 in gastric
cancer relative to adjacent non-cancerous tissue. The
uncontrolled proliferation of neoplastic cells requires
dramatic changes in energy metabolism [18], in which
the primary metabolic fuel and nitrogen source for
tumor cells in glutamine [19-21]. Glutamine is known
to exert influence on a number of signaling pathways
that contribute to tumor growth [22], and is addition-
ally correlated with maintaining the TCA cycle and sup-
porting NADPH production when glucose supply is
limited [23].
While glutamine is not an essential amino acid, it plays
an important role in maintaining the intestinal barrier
structure and immune function. Within the three mamma-
lian system A amino acid transporters, SLC38A1 has the
highest affinity for glutamine, and is strongly expressed in
glutamatergic neurons [24].
Low blood glutamine concentration has been found in
patients with gastric carcinoma and conversely increased
in the mucous membrane adjacent to the malignant tissue
[25]. It is possible that ectopic activation of SLC38A1 may
reflect a compensatory mechanism that confers a survival
advantage.SLC38A1 expression in gastric cancer and other
malignancies
In the present study, we found an increased expression of
SLC38A1 in gastric carcinomas, relative to adjacent non-
cancerous gastric mucosa, suggesting that SLC38A1 might
play an important part in gastric cancer malignant trans-
formation. Enhanced SLC38A1 expression has been ob-
served in several other types of malignancies, including
liver cancer [6], Hilar cholangiocarcinoma [16] and C6 gli-
oma [26]. An elevated expression of SLC38A1 has been
found to be closely linked to differentiation status, lymph
node metastasis and TNM staging, and is thus implicated
in the growth, invasion, metastasis and progression of
gastric carcinomas.
Figure 2 Association between SLC38A1 expression and survival duration in patients with gastric cancer. Kaplan-Meier survival analysis
showed median survival of 46.69vs.69.7 months in patients with positive vs. negative SLC38A1 expression (P = 0.002).
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Consistent with the observation in HepG2 liver cancer
cell lines [6], our study showed that inhibiting SLC38A1
expression with siRNA decreased the growth of cultured
SH-10-TC cells, thus indicating an overexpression of
SLC38A1 contributes to oncogenesis of gastric cancer
through promoting cell proliferation. Inhibiting SLC38A1
expression also reduced cell migration, providing evidence
for increased cell migration as a mechanism for enhanced
metastatic potential, and local invasiveness of SLC38A1-
expressing tumor cells.
In breast cancer, scientists discovered that 17 beta-
estradiol specifically increased System A activity by two
to four-fold in estrogen receptor positive cell lines, with
a maximum stimulation observed 48 h after estrogen-
treatment. In estrogen receptor negative cell lines,





Size (≤ 6 cm vs. > 6 cm) 1.816 1.429
TNM (I/II vs. III) 4.214 3.292
Differentiation (high/moderate vs. low/undifferentiated) 1.876 1.509
Nerve invasion (negative vs. positive) 2.070 1.421
Lymphovascular invasion (negative vs. positive) 2.664 1.770
PCNA (negative vs. positive) 1.794 1.174
P53 (negative vs. positive) 1.277 1.024
SLC38A1 (negative vs. positive) 1.191 1.065evidence that estrogen receptors play a role in the acti-
vation of system A by estrogen [27]. In liver cancer,
System A amino acid transporters produced a different
kind of inactivation and substrate protection in membrane
vesicles and reconstituted proteoliposomes, supporting the
hypothesis that there were inherent differences presented
in System A carriers in normal and transformed liver tissue
[28]. In the current study, we found enhanced SCL38A1
expression in gastric cancer, which supported the implica-
tion of glutamine metabolism in tumors [29-31]. Interest-
ingly, certain cancer cell lines are dependent on glutamine
despite the fact that glutamine is a nonessential amino
acid [32]. To be utilized by tumor cells, glutamine must
be transported into tumor cell mitochondria. This
implies that SLC38A1 could transport glutamine, and
thus play an important role in neoplastic progression/
development.c significance of individual clinicopathological factors
ariate analysis Multivariate analysis
5.0% CI P value HR 95.0% CI P value
r Upper Lower Upper
2.309 .000 1.327 1.039 1.696 .024
5.393 .000 3.416 2.637 4.424 .000
2.332 .000 1.565 1.249 1.960 .000
3.015 .000 1.353 .910 2.011 .135
4.011 .000 1.931 1.258 2.964 .003
2.742 0.007 1.695 1.098 2.617 .017
1.593 0.03 1.046 .835 1.310 .695
1.332 0.002 1.122 1.001 1.258 .041























Figure 3 Silencing SLC38A1 with siRNA in SH-10-TC cells and experiments in vitro. (A) Representative Western blot in the siRNA
experiments. siRNA #2 reduced the SLC38A1 transcript by >70% in comparison to scrambled control (lane1 and 6). GAPDH was used as the
internal control. (B) CCK-8 assay shows si-SLC38A1 significantly inhibited the cell growth of SH-10-TC cells. (C) Upper panel: si-SLC38A1 decreased
the migration of SH-10-TC cells in transwell chambers, compared to parental cells and si-Ctl group. Lower panel: migrated cells on the surface of
the membrane (Columns, mean; bars, SD. *, P < 0.01 vs. scrambled control).
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clinicopathological characteristics as well as prognosis
in patients with GC
Upon further investigation of the relationship between
SLC38A1 and clinicopathological factors, we found that
overexpression of SLC38A1 was strongly associated with
patient age, differentiation status, lymph node metasta-
sis, TNM stage and the expression of PCNA, whereas no
significant association was found in patient gender, tumor
size, tumor location, operation manner, lymphovascular
invasion, depth of tumor invasion, and p53 expression.
These results indicated that SLC38A1 plays a central role
in the malignant progression of gastric carcinomas.Risk factors for gastric cancers have been reported in a
number of studies, including differentiation, [33] nerve
invasion [33], lymphovascular invasion [33], size [13,34],
TNM stage [34], and some molecular markers [35]. Our
study confirmed that differentiation, lymphovascular in-
vasion and the TNM stage were independent predictors
for gastric cancer. We additionally found that SLC38A1 ex-
pression alone was a prognostic factor, with its prognostic
value in multivariate survival analysis for patients who
underwent gastrectomy. Therefore, we supposed that over-
expression of SLC38A1 is a significant factor associated
with a poor prognosis, and might be a marker to forecast
gastric cancer patients’ recurrence and survival. Secondly,
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closely and/or undergo more positive treatment.
Conclusion
In conclusion, our study showed that SLC38A1 expression
was closely associated with age, differentiation status,
lymph node metastasis, TNM stage and PCNA expression,
as well as a worse prognosis in patients with gastric can-
cer. The results from the experiments using cultured gas-
tric cancer cells indicated that SLC38A1 expression could
be used as an indicator of disease aggressiveness. Over-
all, these findings could be useful in developing a novel
molecular target for individualized treatment of gastric
cancer.
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